Pharmaceutical News

RSS

Many community hospitals prescribe ineffective antibiotics for patients with bloodstream infections

Growing drug resistance, a high prevalence of S. aureus bacteria and ineffective antibiotics prescribed to one in three patients are among the challenges facing community hospitals in treating patients with serious bloodstream infections, according to researchers at Duke Medicine.

19 Mar 2014

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.

19 Mar 2014

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018.

19 Mar 2014

Scientists build tiny "molecular drill bits" that kill bacteria by bursting through their protective cell walls

In response to drug-resistant "superbugs" that send millions of people to hospitals around the world, scientists are building tiny, "molecular drill bits" that kill bacteria by bursting through their protective cell walls.

18 Mar 2014

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

18 Mar 2014

Children treated with stimulants for ADHD experienced BMI rebound in late adolescence

A new study from researchers at Johns Hopkins Bloomberg School of Public Health found that children treated with stimulants for attention deficit hyperactivity disorder (ADHD) experienced slower body mass index (BMI) growth than their undiagnosed or untreated peers, followed by a rapid rebound of BMI that exceeded that of children with no history of ADHD or stimulant use and that could continue to obesity.

18 Mar 2014

Children with prenatal methamphetamine exposure 2.8 times more likely to have cognitive problem

In the only long-term, National Institutes of Health-funded study of prenatal methamphetamine exposure and child outcome, researchers found youngsters exposed to the potent illegal drug before birth had increased cognitive problems at age 7.5 years, highlighting the need for early intervention to improve academic outcomes and reduce the potential for negative behaviors, according to the study published online by The Journal of Pediatrics.

18 Mar 2014

New case study reveals how to safely switch between anticoagulants for stroke prevention

With the availability of newer oral anticoagulants, the latest online case study from NPS MedicineWise helps health professionals navigate this changing area and understand the range of treatment options for managing stroke prevention in people with non-valvular atrial fibrillation.

18 Mar 2014

Researchers examine how diabetes drug can benefit cancer patients

For several years, a class of anti-diabetic drugs known as biguanides, has been associated with anti-cancer properties. A number of retrospective studies have shown that the widely used diabetes drug metformin can benefit some cancer patients.

18 Mar 2014

Uptake for HPV jab below 80% required to make significant impact on cervical cancer

Young women who are most at risk of developing cervical cancer are the least likely to be offered the protective HPV jab and to complete the full course when they are, reveals research published online in the journal Sexually Transmitted Infections.

18 Mar 2014

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

A new type of drug could help to combat growing antibiotic resistance, a study finds. Medicines that stop bacteria from harming their hosts, rather than kill them, could prevent bugs from evolving resistance to drug treatments, a review of research in the field suggests.

18 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Healthy children attending day-care centres have a significantly lower risk of getting diarrhoea or respiratory tract infections when given a daily supplement of Lactobacillus reuteri Protectis, a study in 336 children shows. "Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes.

17 Mar 2014

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.

17 Mar 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

PRP injections provide short- and long-term pain relief for patients with severe chronic hip bursitis

Chronic hip bursitis is a common yet difficult condition to treat successfully. A recent study, presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, compared the results of PRP and cortisone injections in patients with severe chronic hip (greater trochanteric) bursitis.

14 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

13 Mar 2014

Pharmaceutical News

Many community hospitals prescribe ineffective antibiotics for patients with bloodstream infections

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

Chemical engineers design way to manufacture peptides in mere hours

Scientists build tiny "molecular drill bits" that kill bacteria by bursting through their protective cell walls

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

Children treated with stimulants for ADHD experienced BMI rebound in late adolescence

Children with prenatal methamphetamine exposure 2.8 times more likely to have cognitive problem

New case study reveals how to safely switch between anticoagulants for stroke prevention

Researchers examine how diabetes drug can benefit cancer patients

Uptake for HPV jab below 80% required to make significant impact on cervical cancer

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

Merck's NOXAFIL injection gets FDA approval for intravenous use

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

PRP injections provide short- and long-term pain relief for patients with severe chronic hip bursitis

Researcher discover new chemical class that attacks two key cancer cell building block targets

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News